Clinical Trial Update: Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment [Phase 2]

View source ↗

Summary

This Phase 2 trial update reports efficacy and safety data for LP-003 in adults with chronic spontaneous urticaria who remain symptomatic despite H1 antihistami…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• LP-003

Snippet

Sponsor: Longbio Pharma | Conditions: Chronic Spontaneous Urticaria | Phase 2 | Status: COMPLETED